Physician profile
John M Mcdonald
NPI 1467496869
$10,636.68
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,665 · 2022: $1,575 · 2023: $6,783 · 2024: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,295 · Education: $64.50 · Food and Beverage: $37.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,295.00 |
| Education | $64.50 |
| Food and Beverage | $37.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,614.50 | 2023-2024 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $4,410.00 | 2021-2024 | Lynparza |
| Seagen INC. | $1,575.00 | 2022 | |
| Eisai INC. | $37.18 | 2023-2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.